Patents by Inventor Gwo-Shu Mary Lee

Gwo-Shu Mary Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20220042105
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Application
    Filed: June 17, 2021
    Publication date: February 10, 2022
    Inventors: CHRISTOPHER SWEENEY, PHILIP KANTOFF, GWO-SHU MARY LEE, KAZUMASA KOMURA
  • Methods for predicting likelihood of responding to treatment
    Patent number: 11214837
    Abstract: The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: January 4, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Philip W. Kantoff, Ming Yang, Gwo-Shu Mary Lee, Tong Sun, Wanling Xie
  • Compositions and methods for screening and diagnosis of prostate cancer
    Patent number: 11066708
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: July 20, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Christopher Sweeney, Philip Kantoff, Gwo-Shu Mary Lee, Kazumasa Komura
  • METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT
    Publication number: 20190284634
    Abstract: The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 19, 2019
    Inventors: Philip W. Kantoff, Ming Yang, Gwo-Shu Mary Lee, Tong Sun, Wanling Xie
  • Methods for predicting likelihood of responding to treatment
    Patent number: 10273544
    Abstract: The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: April 30, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Philip W. Kantoff, Ming Yang, Gwo-Shu Mary Lee, Tong Sun, Wanling Xie
  • COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20190024185
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Inventors: CHRISTOPHER SWEENEY, PHILIP KANTOFF, GWO-SHU MARY LEE, KAZUMASA KOMURA
  • METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT
    Publication number: 20130095481
    Abstract: The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.
    Type: Application
    Filed: February 11, 2011
    Publication date: April 18, 2013
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Philip W. Kantoff, Ming Yang, Gwo-Shu Mary Lee, Tong Sun, Wanling Xie